level in human endometriotic cells. 3 Endometriotic tissue contains not only ER but also aromatase, an enzyme that catalyzes the conversion of androgens to estrogens, suggesting that local estrogen production may increase the estrogen concentration. 4, 5 Thus, the current medical therapies for endometriosis aim to decrease ovarian estrogen production and or counteract estrogen effects with the use of GnRH agonists, progestins, danazol, and oral contraceptives (OCs). However, due to their limited effectiveness and side-effects, alternative therapies that have fewer side-effects in estrogen target tissues are needed. Emerging newer treatment options include aromatase inhibitors, selective estrogen receptor modulators (SERMs), selective progesterone receptor modulators (SPRMs), and antiangiogenic agents. 6 SERMs, used for treatment of infertility, breast cancer, and osteoporosis prevention, have a spectrum of ER agonistic/antagonistic activity depending on the target tissue. They interact with ER and block the hormonal signaling pathway, 7 and have been considered for using in the treatment of endometriosis due to their antiproliferative effects on the endometrium. 8 Tamoxifen (a first generation SERM) reduced the incidence of breast cancer in high-risk patients, but has the increased risk of development and progression of endometrial cancer. 9 Unlike tamoxifen, raloxifene (a second-generation SERM) do not increase the risk of endometrial cancer and is approved for long-term treatment in the prevention of osteoporotic fractures and for the reduction in invasive breast cancer risk in postmenopausal women. 10, 11 One randomized study evaluated whether raloxifene was effective in the treatment of chronic pelvic pain in women with endometriosis. However, this trial had to be terminated early when the raloxifene group experienced pain and had second surgery significantly sooner than the placebo group. 12 Newer generation SERM, bazedoxifene (BZA), also prevented and treated post-menopausal osteoporosis without adverse stimulation of the breast and endometrium. 13 Recently, a tissue-selective estrogen complex (TSEC), which combines BZA and conjugated estrogen (CE), was developed to maximize the tissue-specific effects of SERM and minimize their side-effects. TSEC has an anti-estrogenic effect on the growth of breast cancer cells and prevents the development of endometrial hyperplasia in post-menopausal women.
14-16
The suppressive effect of TSEC on ectopic lesion growth in mice with surgically induced endometriosis has also been reported.
17,18
However, the effectiveness of BZA alone or TSEC on endometriosis in humans has yet to be evaluated. 
| MATERIAL S AND ME THODS

| Animals
All procedures were performed in accordance with protocols approved by the Animal Care and Use Committee of Tottori University
Faculty of Medicine. Four-week-old BALB/c female juvenile mice were purchased from Japan SLC (Shizuoka, Japan) and allowed to have at least 1 week of acclimation to the laboratory's conditions before initiating the experiment.
| Induction of endometriosis
All mice were ovariectomized and then injected subcutaneous (s.c) with estradiol (E2) (0.5 μg/mouse; Fuji Pharma, Tokyo, Japan) once per week for 6 weeks. Two weeks after ovariectomy, the whole uteri from donor mice (n = 18) were removed en bloc after euthanasia, washed in sterile saline, divided into two horns, slit with a linear incision longitudinally, and minced (approximately 0.5 mm in diameter) with dissecting scissors. To create experimental endometriosis, recipient mice (n = 35) were anesthetized using pentobarbital sodium (50 mg/kg). Laparotomy was performed by 0.5 cm subabdominal midline incision, and minced donor tissue (1:2 donor uterus to host ratio) in 250 μL saline was injected into the peritoneal cavity of recipient mice. Finally, the peritoneum was sutured.
| Treatment
After induction, recipient mice were treated with vehicle (n = 10; sa- and injected twice a week after considering the short half-life of LPS (data not shown). The dosages of SR and BZA were determined according to the previous study using ovariectomized rat model (unpublished data), and the literature evaluated the efficacy of BZA, respectively. 30 SR was provided by Nobel pharma Co. (Tokyo, Japan).
| Tissues collection
After 4 weeks of treatment, mice (11 weeks of age) were killed and the peritoneal cavities of the mice were thoroughly inspected.
Uteri and endometriosis-like lesions were carefully removed, weighed, measured, and photographed to document in situ images using a microscope. The surface area (square millimeters) of each endometriosis-like lesion was calculated by multiplying length (millimeters) by width (millimeters). Using Image-J (NIH, Bethesda, MD, USA), the surface area of each lesion could be calculated by the manual measurement of perimeter. Then, the lesions were placed in formalin or in RNAlater TM solution (Life Technologies, Tokyo, Japan),
and frozen immediately at −80°C for later use.
| Real-time RT-PCR
RNA purification, cDNA synthesis, and qPCR were performed as described previously. 22 Total RNA was extracted from the 
| Immunohistochemistry (IHC)
IHC was performed on formalin-fixed, paraffin-embedded endometriosis-like tissue which is cut into 5-μm sections. Slides were deparaffinized through a series of xylene and ethanol washes.
Immunohistochemical analysis was performed as previously described. 22 The primary antibodies used were ERα Negative control slides were incubated similarly, but the primary antibody was replaced with PBS.
| Statistical analysis
All experiments were repeated a minimum of three times. Statistical significance was assessed using JMP software (SAS Institute, Cary, NC, USA). Data were analyzed using one-way ANOVA, followed by LPS alone group, respectively (P < 0.05; Figure 1D ). On the other hand, no significant differences in uterine weight ( Figure 1E ), and body weight (data not shown) were found between the groups.
| Expression of inflammatory-associated cytokines and estrogen receptor after SR-16234 treatment
Real-time RT-PCR analysis demonstrated SR and BZA treatment reduced the LPS-enhanced Vegf, Il-6, Ptgs-2 and Ccl-2 mRNA expression in endometriosis-like lesions (P < 0.05; Figure 2A ), whereas the expression in eutopic endometrium was not different ( Figure 2B ).
ERα and ERβ mRNA expression in endometriosis-like lesions, and eutopic endometrium were also analyzed. In lesions, levels of ERα and ERβ were increased by the addition of LPS, and SR significantly decreased those mRNA expressions. BZA treatment reduced only ERα mRNA (P < 0.05; Figure 3A) . In eutopic endometrium, the effect of LPS on ERα and ERβ was insignificant, and there were no Figure 3B ). In contrast, lesions formed in the vehicle and SR-treated mice expressed low levels of ERβ, and ERβ expression was not significantly different by treatment (data not shown).
| Effect of SR-16234 on cell proliferation, angiogenesis, inflammation, and NF-κB phosphorylation
To evaluate the proliferative activity of lesions, the ratio of Ki67- 
| D ISCUSS I ON
SR-16234 is a novel alternative treatment for endometriosis. In this study, we demonstrated that SR effectively suppressed the growth, and inflammatory-associated genes expression in endometriosislike lesions without inducing endometrial growth. We have compared the efficacy of SR with BZA, which is third generation SERM.
Interestingly, SR seemed to have a more repressive effect than BZA in the growth of murine endometriosis-like lesions. We have also
shown the antiproliferative, anti-inflammatory, and anti-angiogenic 
31-33
Beyond the estrogen-dependent nature of endometriosis, the distinct ER expression profile in endometriosis has also been demonstrated. 2, 3, 34 In humans, so far, a higher ERβ, and a lower ERα expression in endometriotic tissues, which is in the inverse relationship in the endometrium, has been reported. inflammation, and proliferation of ectopic lesions. 35 The gain of ERβ function study also revealed that ERβ enhances adhesion, invasion, and inflammation signaling for the establishment of murine ectopic lesions. 2 However, the available evidence regarding the specific contribution of each ER isoform in murine endometriosis-like lesions is contradictory. 34 In the present study, we showed that the mRNA expression of the ERα and ERβ in murine endometriosis-like lesions were significantly attenuated by SR treatment. By H-score analysis, SR significantly decreased the expression of ERα in epithelial and stromal cells of murine lesions. Intriguingly, in our study, by both real-time RT-PCR, and IHC, lesions formed in all groups expressed low levels of ERβ. A possible explanation is that the endometriosis-like lesions we examined were originated from mouse uterine tissue, where ERα is dominant. We believe that it is difficult to detect the ERβ by IHC in mouse uterus and human uterus. It has also been demonstrated that ERβ protein is expressed in a limited number of normal and cancer tissue types, with the highest expression detected in ovary. 37 Other possibilities of differential regulation of ERβ in murine lesions between our study and previous reports 2,38 might be attributable to the use of different antibodies and pharmacological inhibition.
Currently, most of the medical treatment of endometriosisassociated pain is based on suppressing estrogen production, which creates a relatively hypoestrogenic environment that inhibits ectopic endometrial growth and prevents disease progression. 6 However, due to their estrogen-deficiency side-effects, alternative effective therapies that are appropriate for long-term use is needed, and certain ER modulators have been proposed to alleviate the clinical symptoms of endometriosis. SERMs display ER agonist and antagonistic effects in a tissue-specific profile.
They interact with ER and block the hormonal signaling pathway, leading to a reduction in estrogen activity. However, in this study, because of the excessive estrogen environment, we could not study the signaling pathways leading to anti-inflammatory response induced by SR in endometriosis-like lesions.
Collectively, our findings reveal that SR is effective in suppressing murine endometriosis-like lesions growth by affecting key aspects of cell proliferation, angiogenesis, and inflammatory activity, which are crucial for establishment, progression, and recurrence of the disease. Further experiments using animal models as well as clinical trials will be helpful to explore the effectiveness of SR for treating endometriosis.
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